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DOI 10.1016/j.ccr.2010.12.019SUMMARYMDM2 plays a key role in modulating p53 function. The MDM2 SNP309T > G promoter polymorphism
enhances Sp1 binding and has been linked to cancer risk and young age at diagnosis although with conflict-
ing evidence. We report a second MDM2 promoter polymorphism, SNP285G > C, residing on the SNP309G
allele. SNP285C occurs in Caucasians only, where 7.7% (95% CI 7.6%–7.8%) of healthy individuals carry the
SNP285C/309G haplotype. In vitro analyses reveals that SNP309G enhances but SNP285C strongly reduces
Sp1 promoter binding. ComparingMDM2 promoter status among different cohorts of ovarian (n = 1993) and
breast (n = 1973) cancer patients versus healthy controls (n = 3646), SNP285C reduced the risk of both ovarian
(OR 0.74; CI 0.58–0.94) and breast cancer (OR 0.79; CI 0.62–1.00) among SNP309G carriers.Significance
The MDM2 promoter polymorphism SNP285C diminishes Sp1 transcription factor binding and reduces risk of breast and
ovarian cancer among Caucasians. SNP285C, which forms a distinct haplotype with SNP309G, is a young polymorphism
that seems to rapidly expand within the Caucasian population; in our study, 7.7% out of 3991 healthy individuals carried
the SNP285C/309G haplotype. The distribution of the SNP285C/309G haplotype between populations provides information
considering phylogenetic selection of MDM2 variants. Further, SNP285C may explain why cancer risk studies related to
MDM2 SNP309 status have provided different results in Caucasian compared with Asian populations.
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Table 1. Distribution ofMDM2 Promoter Haplotypes (Alleles) with Respect to SNP285 and SNP309 in Healthy Controls from Different
Populations
Haplotype
285–309
Norwaya Netherlandsa UK Finland China
n (%) n (%) n (%) n (%) n (%)
G-T 1739 (65.0) 1565 (66.3) 452 (65.5) 205 (56.3) 347 (54.4)
G-G 826 (30.9) 704 (29.8) 213 (30.9) 156 (42.9) 291 (45.6)
C-G 109 (4.1) 93 (3.9) 25 (3.6) 3 (0.8) 0 (0)
C-T 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 2674 (100) 2362 (100) 690 (100) 364 (100) 638 (100)
See also Tables S1–S3.
a Identical to cohorts used for cancer risk evaluation (Tables 3 and 4).
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The MDM2 Promoter SNP285C Reduces Cancer RiskINTRODUCTION
TheMDM2(MouseDoubleMinute2homolog)phosphoproteinplays
a central function in cell cycle control. It binds to and inhibits the
function of the pivotal growth arrest and apoptosis regulator p53
(the protein coded for by the TP53 gene) and interacts with several
other major proteins involved in these cellular processes, like pRb
(Xiao et al., 1995) and E2F1 (Martin et al., 1995). MDM2 knockout
leads to embryonic death in mice, a characteristic that is dimin-
ished inMDM2/TP53 double-knockouts (Toledo andWahl, 2006).
MDM2 amplification has been considered as an alternative
mechanism of p53 inactivation in several tumor forms (Momand
et al., 1992; Oliner et al., 1992). Subsequently, a polymorphism
(SNP309T > G; rs2279744) in the MDM2 intronic promoter (P2)
was found to enhance Sp1 transcription factor binding and to
associate with increased MDM2 expression (Bond et al., 2004).
The 309G polymorphism has been related to early cancer
development among individuals harboring TP53 germline muta-
tions (Li-Fraumeni syndrome), young age at diagnosis of soft
tissue sarcomas, as well as ‘‘estrogen receptor (ER) rich’’ breast
cancer among women with wild-type TP53 (Bond et al., 2004,
2006). A recent study revealing MDM2SNP309G/G mice to be
more tumor prone than MDM2SNP309T/T mice (Post et al., 2010)
further corroborated the impact of the SNP309G allele on cancer
risk. However, case-control studies linking this polymorphism to
risk of tumor development and age of diagnosis in different types
of solid tumors have provided conflicting results, with a bias
toward positive associations in Asian populations and negative
results among Caucasians (Economopoulos and Sergentanis,
2010; Hu et al., 2007), including a large study of >5000 Western
European breast cancer patients (Schmidt et al., 2007). So far,
studies of ovarian cancer have been small (Campbell et al.,
2006; Galic et al., 2007; Kang et al., 2009; Ueda et al., 2009)
and some have been restricted to BRCA1/2 mutation carriers
(Copsonet al., 2006;Nechushtanet al., 2009;Yardenet al., 2008).
Following our discovery of a second MDM2 promoter poly-
morphism, SNP285, we aimed at exploring this variant’s effect
on Sp1 binding, its distribution between different ethnic groups
and its impact on risk of breast and ovarian cancer.
RESULTS
MDM2 Promoter Polymorphisms
Studying the MDM2 309T > G promoter polymorphism in
Norwegian cancer patients and healthy controls we observed274 Cancer Cell 19, 273–282, February 15, 2011 ª2011 Elsevier Inc.four nucleotide substitutions in the intronic promoter of
MDM2 (promoter P2). In addition to the previously reported
SNP309T > G, we observed two individuals harboring an
adenine in this position (one healthy control harboring
a SNP309TA genotype and one ovarian cancer patient harboring
a SNP309GA genotype). We also observed one healthy control
harboring a G to A transition 14 bp upstream of SNP309 (position
295). Due to the fact that these two variants were observed in
only two and one out of several thousand individuals, no further
studies were performed with emphasis on these rare variants.
Concomitantly with a Scottish group (Paulin et al., 2008), we
discovered a G to C transversion located only 24 bp upstream
of SNP309 (SNP285) in theMDM2 intronic promoter (P2). Based
on initial screenings, we estimated the frequency of this variant
among Norwegian individuals to be approximately 8%.
SNP285C was observed in individuals harboring the SNP309G
only (Table 1), and subsequent statistical calculations based
on the distribution of SNP285C across large Norwegian and
Dutch cohorts strongly indicate SNP285C/309G to be a distinct
haplotype (p < 1.0 3 1010).
SNP285G>C Diminishes Sp1 Transcription Factor
Binding to the MDM2 Promoter
To assess potential biological effects of the SNP285C, we eval-
uated Sp1 binding by in silico predictions using the JASPAR
database (Sandelin et al., 2004). While this analysis predicted
SNP309G to enhance Sp1 binding by extending a Sp1 binding
site (as previously reported by Bond et al., 2004), interestingly,
SNP285C was predicted to reduce Sp1 binding at an adjacent
binding site.
Next, we determined the binding strength between Sp1 and
the differentMDM2 promoter haplotypes in vitro, through assays
measuring changes in surface plasmon resonance (SPR). In
these binding analyses, double-stranded DNA 104 mers
representing the different variants of the MDM2 promoter were
injected into a flow over the ligand Sp1 protein linked to a chip
(Figure 1). DNA binding to the Sp1-coated chip, as opposed to
reference, confirmed recombinant Sp1 to retain its DNA binding
capability after being linked to the chip surface.
Notably, Sp1-MDM2-promoter binding curves did not fit a 1:1
binding model; the curves were found best fitted to a heteroge-
neous ligand model, indicating more than one Sp1 molecules to
bind each MDM2-promoter fragment. This finding is consistent
with the in silico analysis predicting SNP285 and SNP309 to be
located in two adjacent Sp1 binding sites.
MDM2 gene
WT
SNP309G
SNP285C/309G
SNP285C
DNA flow over Sp1 coated chip
GGGGGCCGGGGGCTGCGGGGCCGCTTCGGCGCGGGA
GGGGGCCGGGGGCTGCGGGGCCGCTGCGGCGCGGGA
GCGGGCCGGGGGCTGCGGGGCCGCTGCGGCGCGGGA
GCGGGCCGGGGGCTGCGGGGCCGCTTCGGCGCGGGA
2NOXE1NOXE
RU
Sp1
WT
WT
WT
WT
309G
285C/
309G
285C
time
48.5*
89.4*
122*
100*
Figure 1. In Vitro Assay for the Effect of SNP285 and SNP309 on Sp1 Binding to the MDM2 Promoter
DNA fragments containing a small element of the intronicMDM2 promoter, P2 (position 284–319 downstream of exon 1, linked to phage-lambda DNA, increasing
fragment size to 104 bp) were amplified by PCR. Predicted Sp1 binding sites within this element are denoted in bold. Fragments containing SNP285C (encircled
green) and SNP309G (encircled red) were used together with recombinant human Sp1 protein in biomolecular interaction analyses (BIA), performed on the
BIACORE T100. In brief, the DNA fragments were passed over a Series S sensor chip CM5 coated with Sp1. DNA binding to Sp1 causes changes in the surface
plasmon resonance (SPR), which was recorded as RUs (1 RU corresponds to 106 refractive index units). Based on SPR, binding curves were generated and
calculations of relative binding strengths were performed using the BIA evaluation software version 2.0.1. *Numbers indicate relative binding strength, as
percentage of wild-type (WT).
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The MDM2 Promoter SNP285C Reduces Cancer RiskUsing the ‘‘wild-type’’ SNP285G/309T haplotype as reference
(100%), pairwise analysis revealed SNP309G to enhance Sp1
protein binding to 122%, confirming previous results obtained
with a different technique (Bond et al., 2004). In contrast,
SNP285C reduced Sp1 binding to only 48.5% of that of the
SNP285G/309T haplotype. Importantly, a fragment representing
the double polymorphic SNP285C/309G haplotype bound Sp1
with an affinity of 89.4% of that of the wild-type SNP285G/309T
haplotype (Figure 1). All differences in relative binding strength
were confirmed by replicates and separate pairwise analyses of
all possible combinations of the polymorphic variants on the
same chip (12 different experiments in total).
SNP285G>C Is Present in Caucasian Populations Only
To evaluate the global distribution of SNP285C, we screened for
this polymorphism in an extended group of Norwegian healthyCindividuals (n = 1337), closely related Caucasian populations
(Dutch; n = 1181 and British; n = 345), a Caucasian population
with a different historical migratory pattern (Finnish; n = 182),
and an Asian group (Chinese; n = 319). These data are summa-
rized in Tables 1 and 2. A detailed overview of SNP285 geno-
types within the different SNP309 genotype-groups is given in
Table S1 (available online) and subcohorts of Norwegian and
Dutch healthy controls are described in Tables S2 and S3.
The SNP285C/309G haplotype accounted for 11.7% of the
SNP309G alleles both among Norwegians and Dutch individuals,
10.5% among British, and 1.9% among Finnish individuals.
Accordingly, 7.8% of the Norwegian, 7.8% of the Dutch and
7.2% of the British individuals carried this allele, in contrast to
1.6% in the Finnish population. Thus, the prevalence of SNP285
in Norway, The Netherlands and UK combined was 7.7% (95%
CI 7.6%–7.8%) and no difference in the frequency was observedancer Cell 19, 273–282, February 15, 2011 ª2011 Elsevier Inc. 275
Table 2. Distribution ofMDM2 SNP285 Genotypes among Healthy Individuals from Different Populations
SNP285 Genotype
Norwaya Netherlandsa UK Finland China
n (%) n (%) n (%) n (%) n (%)
GG 1233 (92.2) 1089 (92.2) 320 (92.8) 179 (98.4) 319 (100)
GC 99 (7.4) 91 (7.7) 25 (7.2) 3 (1.6) 0 (0)
CC 5 (0.4) 1 (0.1) 0 (0) 0 (0) 0 (0)
Total 1337 (100) 1181 (100) 345 (100) 182 (100) 319 (100)
See also Tables S1–S3.
a Identical to cohorts used for cancer risk evaluation (Tables 3 and 4).
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The MDM2 Promoter SNP285C Reduces Cancer Riskbetween these countries (p = 0.871). In contrast, the frequency in
Finlandwas significantly lower as comparedwith the three former
countries (p = 0.002; Chi-square; multiple comparison). Impor-
tantly, SNP285C was not observed among Chinese individuals.Potential Effects of SNP309 and SNP285 onCancer Risk
Basedonour in vitro results,wehypothesized thatSNP309Gmay
beassociatedwith amoderately elevatedcancer risk. In contrast,
the profound effect of SNP285C on Sp1 binding suggests this
polymorphism to reduce cancer risk. Assuming SNP285C to
antagonize the effect of SNP309G, this may explain contempo-
rary findings indicating SNP309G to increase cancer risk in
most ethnic cohorts but not amongCaucasians (Economopoulos
and Sergentanis, 2010; Hu et al., 2007). To assess a potential
effect of SNP285C on cancer risk, we generated two test hypoth-
eses. First, we postulated that SNP285C diminished the effect of
SNP309G on cancer risk among Caucasians. This hypothesis
could be tested by comparing the effect of SNP309G status on
cancer risk in repeated analysis excluding individuals harboring
the SNP285C/309G haplotype. Second, we postulated that the
SNP285C/309G haplotype reduced cancer risk among
SNP309TG heterozygotes and/or 309GG homozygotes. Thus,
we tested these hypotheses in large cohorts of patients diag-
nosed with either breast or ovarian cancer.SNP285G>C Reduces Risk of Breast Cancer
We genotyped MDM2 SNPs in two unselected breast cancer
cohorts; one Norwegian (n = 956) and one Dutch (n = 1017).
The SNP distributions were compared with representative
healthy control samples obtained from the same countries
(Norway; n = 1337, The Netherlands; n = 1181). Breast cancer
patients were unselected for family history of their disease.Table 3. Distribution ofMDM2 Promoter Haplotypes (with respect to
Healthy Controls
Haplotype
285–309
Ovarian Cancer Bre
n (%) n
G-T 1029 (61.8) 252
G-G 584 (35.1) 129
C-G 51 (3.1) 132
C-T 0 (0) 0
Total 1664 (100) 394
p = 0.001b p =
a Total of Norwegian and Dutch cohorts presented in Tables 1 and 2.
bCompared with healthy controls (Chi square).
276 Cancer Cell 19, 273–282, February 15, 2011 ª2011 Elsevier Inc.The frequencies of MDM2 promoter haplotypes were signifi-
cantly different among breast cancer patients and healthy
controls (p = 0.021) (Table 3). Consistent with the findings of
others in Caucasian populations (Schmidt et al., 2007), we found
no increased breast cancer risk associated with harboring the
SNP309G allele (Table 4). However, excluding individuals
carrying the SNP285C, we found the risk of breast cancer to
be significantly increased among SNP309G carriers (Mantel-
Haenszel (M-H) test adjusted for countries OR 1.15; CI 1.01–
1.30). This finding is consistent with our hypothesis suggesting
the contribution of SNP285C to neutralize the effect of
SNP309G on cancer risk among Caucasians. Notably, the asso-
ciationwas higher among SNP309GGhomozygotes (OR 1.27; CI
1.03–1.55) as compared with SNP309TG heterozygotes (OR
1.11; CI 0.98–1.27).
SNP285C reduced risk of breast cancer among SNP309G
allele carriers (SNP309TG heterozygotes and SNP309GG homo-
zygotes combined; M-H test adjusted for countries; OR 0.79; CI
0.62–1.00). Interestingly, subgroup analysis revealed the effect
of SNP285C to be significant among SNP309GG homozygotes
(M-H; OR 0.55; CI 0.35–0.86) with a minor, non-significant trend
among SNP309TG heterozygotes (M-H; OR 0.91; CI 0.69–1.20)
(Figure 2). Testing for heterogeneity between Dutch and
Norwegian breast cancer patients revealed no significant differ-
ence with respect to SNP285C distribution (p = 0.521), and the
data combined revealed a significantly lower SNP285C/309G
haplotype frequency among breast cancer patients (9.3%) as
compared with healthy controls (11.7%; p = 0.029).SNP285G>C Reduces Risk of Ovarian Cancer
Initially, we genotyped 832 Norwegian patients diagnosed with
an epithelial ovarian carcinoma. Ovarian cancer patients wereSNP285 and SNP309) in Ovarian and Breast Cancer Cases versus
ast Cancer Healthya
(%) n (%)
0 (63.9) 3304 (65.6)
4 (32.8) 1530 (30.4)
(3.3) 202 (4.0)
(0) 0 (0)
6 (100) 5036 (100)
0.021b
Table 4. Effect ofMDM2 SNP309 on Breast and Ovarian Cancer
SNP309
Genotype
SNP285
Genotype
Breast Cancer Ovarian Cancer Healthya
n OR (95% CI)b n OR (95% CI)c n
TT GG 805 1.00 296 1.00 1090
TG GG 813 1.11 (0.98–1.27) 406 1.42 (1.17–1.71) 993
TG GC 97 1.01 (0.77–1.34) 31 0.81 (0.52–1.25) 131
TG GG+GCd 910 1.10 (0.97–1.25) 437 1.34 (1.11–1.62) 1124
GG GG 225 1.27 (1.03–1.55) 80 1.19 (0.87–1.62) 239
GG GC 33 0.69 (0.45–1.06) 19 1.16 (0.65–2.09) 65
GG GG+GCd 258 1.14 (0.95–1.38) 99 1.18 (0.89–1.57) 304
TG+GGd GG 1038 1.15 (1.01–1.30) 486 1.37 (1.14–1.65) 1232
TG+GGd GC 130 0.90 (0.71–1.15) 50 0.91 (0.63–1.31) 196
TG+GGd GG+GCd 1168 1.11 (0.99–1.25) 536 1.31 (1.10–1.57) 1428
a Total of Norwegian and Dutch cohorts presented in Tables 1 and 2.
bOR compared with healthy controls, calculated as common odds ratio adjusted for countries.
cOR compared with initial cohort of Norwegian healthy controls (presented in Tables 1 and 2). For further details on SNP distribution in this cohort and
the validation set of Norwegian healthy controls, see Table S1.
dCombined groups.
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The MDM2 Promoter SNP285C Reduces Cancer Riskunselected for family history, but individuals with mutations
related to hereditary ovarian cancer or Lynch syndromes were
not included.
Similar to what was observed among breast cancer patients,
the distribution of MDM2 promoter haplotypes was significantly
different among ovarian cancer patients compared with healthy
controls (p = 0.001) (Table 3).
We observed an increased risk of ovarian cancer among
SNP309G carriers, in particular among individuals with the0
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CSNP309TG genotype (Table 4). Removing carriers of the
SNP285C/309G haplotype from the analyses, the association
between SNP309G and risk for ovarian cancer was strength-
ened, consistent with our hypothesis suggesting SNP285C to
act as an antagonist toward SNP309G (Table 4).
As for breast cancer, SNP285C significantly reduced the risk
of ovarian cancer among SNP309G allele carriers (SNP309GG
homozygotes and SNP309TG heterozygotes combined: OR
0.67; CI 0.47–0.95) (Figure 2). Stratifying for genotype, a strongSNP309GG
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Figure 2. SNP285C Impact on Risk for
Breast and Ovarian Cancer
Effect of SNP285C on risk for breast (BC) and
ovarian (OC) cancer, versus healthy controls
(HC), among individuals with SNP309TG and/or
GG genotype. Error bars indicate 95% CI.
1,2,3Among these individuals 6(1), 2(2), and 1(3)
harbored the SNP285CC genotype. 4Calculated
as common odd ratio by Mantel-Haenszel test,
adjusting for potential differences between
Norwegian and Dutch cohorts. 5Fischer exact
test calculated based on allelic frequencies.
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Figure 3. SNP285C Impact on Risk of
Ovarian Cancer in Independent Data Sets
Bars represent the OR calculated for the initial
cohort of ovarian cancer patients (OC 1) versus
healthy controls (HC 1), the independent cohort
of ovarian cancer patients (OC2) versus healthy
controls (HC 2) in addition to the corresponding
values for pooled cohorts (OC Tot) among individ-
uals with SNP309TG and/or GG genotype. Error
bars indicate 95% CI.1,2,3,4 Among these individ-
uals, 3(1), 1(2), 4(3), and 5(4) harbored the SNP285CC
genotype.5 OR calculated from initial cohort of
ovarian cancer patients (OC 1) versus initial cohort
of healthy controls; as presented in Figure 2. 6OR
calculated from verification set of ovarian cancer
patients (OC 2) versus verification set of healthy
controls (HC 2). 7OR calculated from total of all
ovarian cancer patients, including the initial cohort
presented in Figure 2. (OC Tot; = OC 1 + OC 2)
versus total of Norwegian healthy controls,
including the initial cohort presented in Figure 2.
8Fischer exact test calculated based on allelic
frequencies.
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The MDM2 Promoter SNP285C Reduces Cancer Riskeffect was observed among individuals carrying the SNP309TG
genotype (OR 0.57; CI 0.37–0.88) while no significant association
was observed in the SNP309GG group (OR 0.98; CI 0.52–1.85).
However, only 19 ovarian cancer patients were carriers of the
SNP285GC/309GG genotype, and the result should be inter-
preted carefully with respect to this subgroup.
The frequency of the SNP285C/309G haplotype among
SNP309G alleles was significantly lower among Norwegian
ovarian cancer patients (8.0%) as comparedwith healthy Norwe-
gians (11.7%; p = 0.022) and Dutch (11.7%; p = 0.027) controls
(combining Norwegian and Dutch control groups; p = 0.011).
SNP285G>C Reduces Risk of Ovarian Cancer
in Independent Patient and Control Cohorts
In order to verify the effect of SNP285C on ovarian cancer risk,
we genotyped SNP285 and SNP309 across an independent
cohort of Norwegian ovarian cancer patients and a second
cohort of healthy Norwegian controls. Here, we wanted to
confirm the hypothesis that SNP285C is associated with
reduced risk of ovarian cancer among carriers of the SNP309TG
genotype. To estimate the sample size needed for this validation,
we took advantage of the results obtained in our initial cohorts
where SNP285C was observed in 7.1% of ovarian cancer
patients and in 11.8% of healthy controls carrying the
SNP309TG genotype. Using a one-sided alpha-value of 0.05
and a beta-value of 0.8, the required number of ovarian cancer
patients and healthy controls, harboring the SNP309TG geno-
type, was 512 in each group. To obtain this number with a prob-
ability >90%, a total number of 1018 ovarian cancer patients and
1153 healthy controls were needed (for full details on calcula-
tions, see Supplemental Experimental Procedures). Obtaining
and analyzing DNA from 1161 new ovarian cancer patients and
1128 new healthy controls, these criteria were fulfilled.278 Cancer Cell 19, 273–282, February 15, 2011 ª2011 Elsevier Inc.While the frequency of SNP285C in the control validation
cohort (7.7%) mirrored the frequency in our first Norwegian
healthy control cohort (7.8%), the prevalence of SNP285C
among ovarian cancer patients in the validation set (6.9%) was
slightly higher than in our initial cohort (6.0%), but the difference
was not statistically significant (p = 0.46).
Analyzing the validation sets of ovarian cancer patients and
healthy controls, SNP285C significantly reduced the risk of
ovarian cancer among SNP309TG heterozygous individuals
(OR 0.65; CI 0.44–0.96). In contrast, SNP285C had no effect on
ovarian cancer risk among SNP309GG homozygous individuals
(OR 1.18; CI 0.65–2.13) (Figure 3). Combining the data from our
initial cohorts and the validation sets, SNP285C strongly
reduced the risk of ovarian cancer among individuals harboring
the SNP309TG genotype (OR 0.63; CI 0.47–0.84).
The differential effect of SNP285C on SNP309TG heterozy-
gotes versus SNP309GG homozygotes with respect to ovarian
cancer risk mirrors the effect observed in our initial dataset (Fig-
ure 3). This contrasts with the results from the breast cancer
cohort, where the effect of SNP285C was observed among indi-
viduals carrying the SNP309GG but not the SNP309TG geno-
type (Figure 2). Importantly, patients in the validation cohort
harboring the SNP285GG/309TG genotype revealed an elevated
risk of ovarian cancer as comparedwith individuals harboring the
SNP285GG/309TT genotype (OR 1.31; CI 1.09–1.57), again
consistent with the results from our first dataset. A differential
effect of MDM2 status in ovarian and breast cancer was further
corroborated by the finding of SNP285C disequilibrium
comparing breast and ovarian cancer patients (initial ovarian
cancer cohort: p = 0.027; verification cohort: p = 0.061; calcula-
tions based on data presented in Figures 2 and 3).
Additionally, we analyzed a small cohort of British ovarian
cancer patients (n = 115). Including these patients (with 345
Cancer Cell
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country did not substantially influence the association (OR
0.67; CI 0.51–0.89 among SNP309TG heterozygotes).
Potential Correlations between MDM2 SNP Status, p53
Arg72Pro, ER Status, and Age at Breast Cancer
Diagnosis
Some studies (Ashton et al., 2009; Ellis et al., 2008; Nunobiki
et al., 2009) have reported a potential interaction between the
p53 Arg72Pro polymorphisms and the MDM2 SNP309G allele.
Analyzing TP53 status among 312 breast cancer patients in
this study, we found no correlation between either of the two
MDM2 promoter polymorphisms and the TP53 Arg72Pro status
(p > 0.40 for all comparisons).
Interestingly, Bond et al. (2006) detected a correlation
between age at diagnosis in breast cancer patients harboring
estrogen receptor (ER)-rich breast tumors, defined as having
>50% of the tumor cells staining positively for the ER. Our data
did not allow a similar subgroup analysis. However, relating
age at diagnosis to MDM2 SNP309 and SNP285 status among
330 breast cancer patients defined as ER positive by conven-
tional criteria (>10% of tumor cells staining positive), we
detected no correlation between MDM2 SNP status and age at
breast cancer diagnosis (p > 0.40 for all comparisons).
DISCUSSION
Germline mutations in high-penetrance genes including BRCA1,
BRCA2, and (rarely) other genes like TP53 are associated with
a high risk of breast cancer. Similarly, BRCA1 and BRCA2muta-
tions are associated with high risk of ovarian cancer. However,
confirmed germline mutations account for less than 5% of all
breast cancers and about 10% of ovarian cancers (for refer-
ences, see ACOG 2009). Thus, recent research has focused on
polymorphisms in ‘‘low-risk’’ genes and their combinations to
explain inherited cancer predisposition. While genome-wide
analysis studies (GWAS) have identified polymorphisms in
different genes to be associated with elevated breast and
ovarian cancer risk, except for a few genes including FGFR2
and TNRC9 (Easton et al., 2007; Yang et al., 2009) conferring
enhanced breast cancer risk of 35% and 28%, such polymor-
phisms are associated with a minor risk increase in the range
of 10%–15% (for references, see Yang et al., 2009).
Importantly, for most genes related to breast and ovarian
cancer risk through GWAS, the functional explanation to their
effects is, at best, incomplete. This contrasts the well-estab-
lished knowledge about the mechanisms by which MDM2
executes its effects on key genes involved in apoptosis as well
as growth arrest (Toledo and Wahl, 2006). The importance of
MDM2 status with respect to cancer growth is illustrated by
the frequent findings of MDM2 overexpression, caused by
gene amplifications or other mechanisms in several tumor forms
(for references, see Bartel et al., 2001). A milestone in this
research area was reachedwith the discovery by Arnold Levine’s
group in 2004 of theMDM2 promoter polymorphism SNP309T >
G enhancing MDM2 expression by increasing Sp1 promoter
binding (Bond et al., 2004) and subsequent studies corrobo-
rating the role of SNP309G as a cancer risk modulator (Bond
et al., 2006; Post et al., 2010). While Bond et al. (2004) reportedCthe effects of the human MDM2 promoter variants in Drosophila
cell lines, this study addresses transcription factor binding to the
MDM2 promoter by use of SPR. Our results revealed SNP309G
to enhance Sp1 binding, while SNP285C and the combined
SNP285C/309G haplotype both reduced Sp1 binding. The
strong effect of the SNP285C polymorphism as compared with
SNP309G on Sp1 binding strength is corroborated by the
different impact of the two polymorphisms on cancer risk. While
additionalMDM2 promoter polymorphisms located on the 309T
allele have been reported in different ethnic groups (Atwal et al.,
2007), the functional effects of these variants remain unknown.
Characterization of the 285C polymorphism with respect to
molecular effects, ethnic distribution, and impact on ovarian
and breast cancer risk expands our understanding of the role
of MDM2 allele variants substantially. We propose that occur-
rence of the 285C polymorphism among Western Caucasians
may account for the discrepancy in previous studies evaluating
the effects of SNP309G in different ethnic populations (Econo-
mopoulos and Sergentanis, 2010; Hu et al., 2007) on cancer
risk. The finding underlines the need of careful interpretations
of disease odds ratios as well as genome-wide associations
obtained from pooled populations with a different ethnic back-
ground, or located in different geographical areas.
Secondary somatic mutations counteracting the effect of
a primary mutation has recently been described as amechanism
circumventing drug sensitivity in cancer cells (Edwards et al.,
2008; Sakai et al., 2008). The present observation of a second
polymorphism antagonizing the effects of another polymorphism
located on the same allele, illustrates similar mechanisms in
a much longer time frame.
Importantly,weobservedasignificantly reduced riskofovarian,
but not breast cancer related to SNP285C among SNP309TG
heterozygotes. Consistent with this finding, we observed an
increased risk of ovarian, but not breast cancer among individuals
harboring theSNP285GG/309TGgenotype (Figure1andTable4).
Importantly, the significantly different effect of SNP285C on
SNP309TG heterozygotes and SNP309GG homozygotes with
respect to ovarian cancer risk was detected in two large indepen-
dent data sets. Taken together, thesedata support thehypothesis
that heterozygosity for SNP309G, and the neutralizing effect of
SNP285C, have significant impact on ovarian cancer risk. In
contrast, the effect of SNP285C on breast cancer risk was
restrictedmainly to individuals carrying theSNP309GGgenotype.
A differential effect ofMDM2 status in ovarian and breast cancer
was corroborated by the finding of SNP285C disequilibrium
(p = 0.027) comparing breast and ovarian cancer patients (Fig-
ure 2). While it is well known that heterozygous carriers of reces-
sive genes may be at risk of diseases different from the major
disease observed in homozygotes (Smirnov and Cheung, 2008),
we here show that such disparity also may be found with respect
to risk of different cancer forms.
Our findings of a second MDM2 promoter polymorphism
(SNP285C) antagonizing the effect of a MDM2 enhancing
polymorphism (SNP309G) may lead to speculations on evolu-
tionary mechanisms selecting for different MDM2 alleles and
the role of theMDM2 – p53 axis in human biology beyond cancer
risk. SNP285C seems to be a young polymorphism that has
arisen in Western Europe. With the very low frequency of
SNP285C observed among Finnish individuals, most likely thisancer Cell 19, 273–282, February 15, 2011 ª2011 Elsevier Inc. 279
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Finland and Western European countries including the United
Kingdom, Holland, and Norway (Peltonen et al., 1999), This
contrasts the ancient 309G polymorphism, found in all ethnic
groups. The fact that SNP285C has already spread to 7.7% of
the Western Caucasian individuals indicate positive selection
for this polymorphism through influence on factors related
to survival and/or reproductive biology. Notably, SNP309G
has been linked to risk of missed abortion (Fang et al., 2009).
Whatever the mechanisms may be, the fact that age at cancer
diagnosis in general exceeds reproductive age suggests mech-
anisms other than cancer risk to be important for the selection of
MDM2 variants.
Regulation of p53 function involves several genes likeMDM2,
ATM, CHEK2, and the Nijmegen Breakthrough Syndrome Gene
(NBS1). The fact that alterations of these genes may partly
substitute for TP53 mutations with respect to modulation of
cancer risk, tumor progression and response to cytotoxic stress
(Buscemi et al., 2001, 2004; Chrisanthar et al., 2008;Meyn, 1999;
Oliner et al., 1992; Varon et al., 2001) underlines the critical
importance of tight control of the entire p53 functional pathway.
While TP53 itself harbors a frequent polymorphism (Arg72Pro),
evidence linking this variant to increased cancer risk is conflict-
ing (Francisco et al., 2010). Some studies have linked MDM2
SNP309 to the TP53 polymorphism Arg72Pro (Ashton et al.,
2009; Ellis et al., 2008; Nunobiki et al., 2009). However, we found
no association between either of the twoMDM2 polymorphisms
and TP53 Arg72Pro status in our data. This observation is in line
with the results from the Breast Cancer Association Consortium
(Schmidt et al., 2007).
In conclusion, MDM2 SNP285C significantly reduced the risk
of breast and ovarian cancer among Caucasians, and revealed
ethnic genetic diversity with respect to the risk of these two
malignancies. The finding of a late polymorphism (SNP285C)
antagonizing an ancient polymorphism (SNP309G) draws atten-
tion to the mechanisms that have driven the phylogenetic selec-
tion of MDM2 variants.
EXPERIMENTAL PROCEDURES
In Silico Predictions of Sp1 Binding to the MDM2 Promoter
Prediction of Sp1 transcription factor binding to the different variants of the
MDM2 promoter was performed using the JASPAR database at http://
jaspar.cgb.ki.se (Sandelin et al., 2004).
Sp1-DNA Binding Analysis
Biomolecular interaction analyses (BIA) were performed on the BIACORE T100
(GE Healthcare, BIACORE AB, Uppsala, Sweden). Series S sensor chip CM5
and amine-coupling reagents, N-ethyl-N0-(3-dimethylaminopropyl) carbodii-
mide (EDC), N-hydroxysuccinimide (NHS), and ethanolamine HCL (Ge Health-
care, Biacore) were used to anchor the human Sp1 protein (Active Motif). CM5
sensor chips, with carboxymethylated dextran matrix, were preconditioned
through three consecutive 10 s injections of 1X HBS-EP buffer (10 mMHEPES
(pH 7.4), 0.15 M NaCl, 3.4 mM EDTA, and 0.05% surfactant P20), with a flow
100 ml/min, followed by two consecutive 10 s injections of 100 mM HCl, two
consecutive injections of 50 mM NaOH, and two consecutive injections of
0.5% SDS. CM5 chip flow cells were activated by 0.4 M EDC and 0.1 M
NHS in a 1:1 ratio (v/v). Levels of 3000–8000 RU of Sp1 protein (20 mg/ml)
were immobilized at 25C with a flow 5 ml/min on each active flow cell. In a
single binding analysis, two of the different double-stranded DNA 104 mers
representing the different variants of the MDM2 promoter with concentration
ranging from 0–400 nM were injected in separate flow cells on the same280 Cancer Cell 19, 273–282, February 15, 2011 ª2011 Elsevier Inc.chip over both the ligand (human recombinant Sp1 protein) and a reference
surface (blank) for binding strength comparison. The analysis temperature was
25C, the contact timewas 60–120 s and the flow rate was 30–100 ml/min. DNA
binding to Sp1-coated Chip, as opposed to reference, confirmed recombinant
Sp1 to retain its activity (DNA binding capability) after being linked to the chip
surface. All MDM2 promoter fragments were compared with the wild-type
variant. Biosensor data were analyzed using the BIAevaluation software
version 2.0.1. Subsequently, all differences in relative binding strength were
confirmed by replicates and separate pairwise analyses of all possible combi-
nations of the polymorphic variants on the same chip (12 different experiments
in total).
Cohorts for Ethnic Comparison
The different ethnic populations used for initial characterization of SNP285C
distribution have been described elsewhere (for details and references, see
Supplemental Experimental Procedures).
Healthy Controls Used for Cancer Risk Comparison
Norwegian healthy controls (n = 1337) were collected from several different
cohorts (see Tables S1 and S2 and Supplemental Experimental Procedures).
Dutch healthy controls (n = 1181) consisted of blood donors from the regions
surrounding the University Hospitals of Rotterdam and Leiden, and a series of
healthy individuals from all over The Netherlands (see Supplemental Experi-
mental Procedures for further details).
Breast Cancer Cohorts
We analyzed samples from 2121 breast cancer patients from several cohorts
previously described (for details and references, see Supplemental Experi-
mental Procedures).
Ovarian Cancer Cohorts
We analyzed samples from 832 women diagnosed with epithelial ovarian
cancer at the Oslo University Hospital Radiumhospitalet in the period between
2002 and 2009. The age range was 18–90 years. Prior to inclusion, pathology
reports had been audited by two of the investigators (M.B. and A.D.).
All patients were counseled and signed a written informed consent before
genotyping. Notably, patients with known mutations related to hereditary
breast and ovarian cancer (BRCA1 or BRCA2) or Lynch syndromes (MSH2)
were not included in the study.
The cohort of ovarian cancer patients used as a verification set (n = 1161)
consisted women diagnosed with epithelial ovarian cancer either at Oslo
University Hospital Radiumhospitalet, or Haukeland University Hospital,
Bergen, in the period between 1993 and 2009. The age rangewas 14–90 years.
Prior to inclusion, pathology reports had been audited by one of the investiga-
tors (A.D. or H.B.S.).
Ethical Considerations
All healthy individuals as well as cancer patients included in the different
cohorts provided informed consent for anonymous use of the blood for scien-
tific research. Each study included in this paper was conducted in accordance
with the Helsinki Declaration. Approval for sample collection and genetic anal-
yses on nonidentified specimens was granted by the following Regional/Insti-
tutional ethical committees: (1) Regional Ethical Committees, Health Regions
of Western, South-Eastern, and Central Norway; (2) The Medical Ethical
Committees of the Leiden University Medical Center, Leiden, and the Erasmus
MC-Daniel den Hoed Cancer Center Rotterdam, The Netherlands; (3) The
Ministry of Social Affairs and Health in Finland and the Ethics Committee of
the Hospital District of Helsinki and Uusimaa, Finland; (4) The Central Man-
chester research ethics committee, UK; (5) The Institutional Review Board of
the Chinese Academy of Medical Sciences Cancer Institute, China.
MDM2 Promoter Screening
All the Norwegian and Dutch samples were analyzed with an identical method.
Thus, a region of the MDM2 promoter containing both SNP285 and SNP309
was amplified by using the DyNazyme EXT polymerase system (FINNZYMES)
according to the manufacturer’s instructions with primers MDM2PF 50-CGG
GAGTTCAGGGTAAAGGT-30 and MDM2PR 50-AGCAAGTCGGTGCTTACC
TG-30. PCR conditions were an initial step of 94C, 40 cycles of 94C for
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7 min. PCR products were sequenced using Big Dye terminator mixture
(Applied Biosystems). All sequencing reactions were carried out with the
same primers as used for PCR amplification. After an initial step of 5 min dena-
turation at 94C, the sequencing reaction was carried out for 40 cycles of 10 s
at 94C, 5 s at 55C, and 4 min at 60C. Capillary gel electrophoresis, data
collection and sequence analysis were performed on an automated DNA
sequencer (ABI 3700). For Norwegian and Dutch samples (both for cases
and controls), 2%–5% of the samples were analyzed in duplicate as assay
quality controls.
Finnish and Chinese samples were genotyped by PCR-based restriction
fragment length polymorphism analyses (PCR-RFLP), while British samples
were analyzed for SNP309 by Taqman-assay and SNP285 by pyrosequencing
(for full details of these analyses, see Supplemental Experimental Procedures).
Statistical Analysis
All statistical analyses were performed using the SPSS/PASW (version
15.0.1/17) software packages. SNP285 and 309 distributions were compared
between Norwegian and Dutch healthy individuals using Chi-square test to
ensure homogeneity in the cohorts used as controls (for calculations, see
Table S3). For calculations of odds ratios, confidence intervals (CI) are given
as 95%. For breast cancer, common odds ratio adjusted for countries
(Mantel-Haenszel test) was used to ensure that the results were not affected
by potential differences between Norwegian and Dutch cohorts. Ovarian
cancer cases (Norwegian) were compared with Norwegian controls. However,
additional analyses, including Dutch controls strengthens all calculations of
the impact of SNP309G and SNP285C on ovarian cancer risk. All p-values
are given as two-sided and p-values from Fischer exact tests are given as
cumulative.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
and three tables and can be found with this article online at doi:10.1016/j.
ccr.2010.12.019.
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